Featured Studies

Researchers are enrolling people with locally advanced or metastatic cancer who are prescribed atezolizumab (alone or with other approved treatments). The study will monitor blood levels to adjust infusion schedules, aiming to see if lower or less frequent doses can be given without reducing effectiveness, over a period of up to 2 years.

Researchers at NCI are developing a new investigational treatment known as TNhYP218 CAR T cells to target and kill tumor cells in people with solid tumors and with those that have high levels of mesothelin (MSLN) including mesothelioma. The study team collects immune cells (T cells); the T cells are genetically modified to target and kill tumor cells to potentially shrink the tumor.

Researchers at @NIDDKgov are studying new methods in treating thyroid cancer that has spread outside the thyroid – to the lymph nodes, lungs, or bones We are now enrolling patients age 18 years and older with thyroid cancer that spread outside the thyroid. All study tests and procedures are provided at no cost. 

Did you know your thyroid gland produces hormones that regulate body temperature, heart rate and metabolism? Physicians want to explore a better method to detect thyroid tumors by using a compound called 68Gallium-DOTATATE. This compound may bind to a tumor and make it visible during a PET/CT scan. This information will help guide future research and treatment.

Doctors at the National Cancer Institute (NCI) are looking for volunteers with metastatic cancers, including breast, ovarian, endometrial, gastrointestinal, genitourinary, hepatobiliary, pancreatic, melanoma, non-small cell lung cancer (NSCLC), and multiple myeloma with solid masses. Potential participants will be evaluated with new immunotherapy treatments utilizing cell transfer immunotherapies in a research trial.

Investigators at the National Cancer Institute (NCI) are enrolling patients with advanced hepatocellular cancers (HCC), in a clinical trial using engineered immune cells, also known as chimeric antigen receptor T-cells or CAR-T cells. In this study, your immune T-cells are collected and modified to target Glypican-3 (GPC3), a protein marker found on the surface of HCC tumors. Researchers hope the altered cells will help identify and fight the cancer cells.

Doctors at the National Institutes of Health (NIH) are conducting a research study for thyroid cancer. Researchers are using a novel imaging technique called 68Gallium DOTATATE PET/CT, which has been proven safe and effective in patients with other tumors - neuroendocrine tumors.

National Cancer Institute (NCI) researchers are conducting a study of patients with IDH-mutated gliomas. This study will test whether stimulating the immune system using the drug nivolumab can shrink recurrent IDH-mutant gliomas with and without hypermutator phenotype or increase the time it takes for them to grow or spread.

Hepatocellular Carcinoma (HCC) is the fifth most common cancer in the world. Patients with advanced HCC survive an average of 6 to 9 months. Researchers at the National Institutes of Health are testing the use of an immunotherapy medication called durvalumab, with two other chemotherapy medications, doxorubicin-eluting beads and bevacizumab. This clinical research study will investigate if this combination of medications can stop the progression of HCC.

Are you looking for a treatment for non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH)? Researchers at the National Institutes of Health (NIH) seek volunteers to participate in a research study. For 30 weeks, participants will receive a medication called semaglutide (typically used for Type 2 diabetes), aiming to improve their liver disease and help them lose weight. The study hopes to better understand liver damage and its treatment in people with these conditions. (En español)